ArticleScientific reports2026
Comprehensive characterization of VSIR reveals dual epigenetic regulation and immune landscape across hematological malignancies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
VISTA (V-domain Immunoglobulin Suppressor of T cell Activation), encoded by VSIR, functions as an inhibitory checkpoint predominantly expressed on myeloid cells. Despite its recognized role in solid tumors, systematic characterization of VSIR regulation and clinical implications in hematological malignancies remains limited. We performed integrative multi-omics analyses of diverse hematological malignancies (> 10,000 transcriptomes) to elucidate VSIR expression patterns, epigenetic regulation, and therapeutic potential. VSIR exhibited preferential upregulation in hematological malignancies, particularly myeloid leukemias. We identified dual epigenetic mechanisms driving VSIR overexpression: promoter hypomethylation progressively intensified from healthy controls through myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML), validated by targeted bisulfite sequencing in 130 clinical samples; chromatin immunoprecipitation sequencing revealed direct transcriptional activation by KMT2A fusion proteins through enrichment of H3K4me3, H3K79me2, and H3K27ac activating marks at the VSIR promoter. Menin inhibitor treatment substantially reduced KMT2A occupancy and histone modifications, confirming Menin-dependent regulation. Similarly, NPM1 mutations promoted VSIR expression through stabilizing Menin-containing chromatin complexes. Functionally, VSIR-high tumors showed enrichment in immune regulatory pathways and predicted favorable immunotherapy responses. Prognostically, elevated VSIR expression conferred adverse outcomes in AML while predicting improved survival in DLBCL and MM. Computationally, VSIR-high patients showed increased likelihood of benefiting from immune checkpoint blockade, validated in real-world immunotherapy cohorts. The elucidated Menin-VSIR regulatory axis suggests potential for combining Menin inhibitors with VISTA checkpoint blockade in KMT2A-rearranged AML. Our findings suggest that VSIR expression is epigenetically dysregulated in hematological malignancies through dual mechanisms, which could inform biomarker-driven patient selection and rational design of combination immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.